ANNEX 3 Linies.pdf - Fundació Institut d'Investigació en Ciències de ...

J NUTR 2009-MAR; 139 (3): 603-610
IF: 4,091
Marín-Gallén S, Clemente X, Planas R, Pujol I, Carrillo J, Carrascal J, Ampudia R, Pujol-Borrell R, Borràs FE, Vives-Pi M
Prevention of experimental type 1 diabetes by immunotheraphy with syngeneic dendritic cells pulsed with antigenspecific
apoptotic bodies
J IMMUNOTHER 2009
IF: 3,203
Martínez-Hernández R, Soler-Botija C, Caselles L, Alias L, Also E, Bernal S, Baiget M, Tizzano EF.
Analysis of the developmental pattern of human myotubes supports a prenatal delay of muscle maturation in spinal muscular
atrophy.
J NEUROPATH EXP NEUR 2009 May; 68(5):474-81
IF: 4,564
Massanella, M; Puigdomenech, I; Cabrera, C; Fernandez-Figueras, MT; Aucher, A; Gaibelet, G; Hudrisier, D; Garcia, E; Bofill, M;
Clotet, B; Blanco, J
Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells
AIDS 2009-JAN 14; 23 (2): 183-188
IF: 4,909
Matilla-Dueñas A, Sánchez I, Corral-Juan M, Dávalos A, Alvarez R, Latorre P.
Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias.
CEREBELLUM 2009 Nov 5. [Epub ahead of print]
IF: 3,280
Minuesa, G; Volk, C; Molina-Arcas, M; Gorboulev, V; Erkizia, I; Arndt, P; Clotet, B; Pastor-Anglada, M; Koepsell, H; Martinez-
Picado, J
Transport of Lamivudine [(-)-beta-L-2 ',3 '-Dideoxy-3 '-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse
Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3
J PHARMACOL EXP THER 2009-APR; 329 (1): 252-261
IF: 4,093
Miura, T; Brockman, MA; Schneidewind, A; Lobritz, M; Pereyra, F; Rathod, A; Block, BL; Brumme, ZL; Brumme, CJ; Baker, B;
Rothchild, AC; Li, B; Trocha, A; Cutrell, E; Frahm, N; Brander, C; Toth, I; Arts, EJ; Allen, TM; Walker, BD
HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced
Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition
J VIROL 2009; 83:2743-2755
IF: 5,150
Murphy, RL; Autran, B; Katlama, C; Brucker, G; Debre, P; Calvez, V; Clotet, B; Clumeck, N; Costagliola, D; Deeks, SG; Dorrell, L;
Gatell, J; Haase, A; Klein, M; Lazzarin, A; Mcmichael, AJ; Papagno, L; Schacker, T; Wain-Hobson, S; Walker, BD; Youle, M
A Step Ahead on the HIV Collaboratory
SCIENCE 2009-juny-05; 324 (5932): 1264-1265
IF: 29,747
Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR.
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of
lamivudine.
J VIROL 2009 Feb;83(4):2038-43. Epub 2008 Nov 19
IF: 5,150
Parera, M; Perez-Alvarez, N; Clotet, B; Martinez, MA
Epistasis among Deleterious Mutations in the HIV-1 Protease
J MOL BIOL 2009-SEP 18; 392 (2): 243-250
IF: 3,871
Perez-Elias, MJ; Morellon, ML; Ortega, E; Hernandez-Quero, J; Rodriguez-Torres, M; Clotet, B; Felizarta, F; Gutierrez, F; Pineda, JA;
Nichols, G; Lou, Y; Wire, MB
Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic
Impairment
ANTIMICROB AGENTS CH 2009 DEC;53:5185-5196
Pàgina 7 de 67